Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 3
2010 5
2011 11
2012 11
2013 7
2014 3
2015 7
2016 11
2017 7
2018 3
2019 1
2020 8
2021 14
2022 13
2023 14
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ji yong jing (6 results)?
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Coronary Artery Calcification Score and the Progression of Chronic Kidney Disease.
Yun HR, Joo YS, Kim HW, Park JT, Chang TI, Son NH, Yoo TH, Kang SW, Sung S, Lee KB, Lee J, Oh KH, Han SH; KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) investigators; KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). Yun HR, et al. J Am Soc Nephrol. 2022 Aug;33(8):1590-1601. doi: 10.1681/ASN.2022010080. Epub 2022 Jun 2. J Am Soc Nephrol. 2022. PMID: 35654602 Free PMC article.
The Anti-Diabetic Pinitol Improves Damaged Fibroblasts.
Jung JY, Shim JH, Cho SH, Bae IH, Yang SH, Kim J, Lim HW, Shin DW. Jung JY, et al. Biomol Ther (Seoul). 2024 Mar 1;32(2):224-230. doi: 10.4062/biomolther.2023.220. Epub 2024 Jan 4. Biomol Ther (Seoul). 2024. PMID: 38173141 Free PMC article.
Intrarenal Renin-Angiotensin System Activation Alters Relationship Between Systolic Blood Pressure and Progression of Chronic Kidney Disease.
Park CH, Kim HW, Park JT, Chang TI, Yoo TH, Lee J, Sung S, Jung JY, Hyun YY, Oh KH, Kang SW, Han SH; on the behalf of the KNOW-CKD (Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease) Investigators. Park CH, et al. Among authors: jung jy. Hypertension. 2023 May;80(5):1024-1034. doi: 10.1161/HYPERTENSIONAHA.122.20824. Epub 2023 Mar 28. Hypertension. 2023. PMID: 37075134
The 2021 KDIGO blood pressure target and the progression of chronic kidney disease: Findings from KNOW-CKD.
Park CH, Kim HW, Park JT, Chang TI, Yoo TH, Park SK, Kim Y, Jung JY, Jeong JC, Oh KH, Kang SW, Han SH; KNOW-CKD (KoreaN Cohort Study for Outcomes in Patients with Chronic Kidney Disease) Investigators. Park CH, et al. Among authors: jung jy. J Intern Med. 2023 Nov;294(5):653-664. doi: 10.1111/joim.13701. Epub 2023 Aug 4. J Intern Med. 2023. PMID: 37538023
119 results